Januvia was approved in October. Does that create a disadvantage for Novartis?
It clearly would have been better if we had launched first—it's always our ambition to be first in the market. But what really
matters is which drug has the better profile, and us having the better profile will definitely help us to compensate for the
Will Novartis run awareness ads to highlight this new class of drugs, or will you stick with branded ads that mention only
At this point I don't want to give you a specific answer. We ultimately have to wait and see what to do in terms of our advertising.
We first need to discover what is our product profile, what is our perceived differentiation [from the] competition, and what
is our competitor doing? For the time being, we are keeping both options open.
Diabetes is becoming an oppressive epidemic, especially here in the United States. What does the future of treatment look
The next level of diabetes treatment really involves developing more fixed-dose combinations. Patients who very often have
concomitant diseases have to take a lot of pills a day. These patients very often are not really fully compliant, and the
availability of powerful fixed-dose combinations will ensure a better outcome based on better efficacy and better compliance
of patients. That is a very critical element.
Ideally the future will hold diabetes drugs that lower HbA1c and that reduce weight gain as one of its side effects. Most
scientific approaches will aim to address those two unmet medical needs.
Is diabetes becoming a rising problem or is there just more awareness now?
It will become a real problem here and beyond the US. There are articles about Europe now, articles that say Europe is becoming
an obese continent. There is also more discussion of this topic in Asia, too. Given the lifestyle we all have, which is a
lot of bad food and too little exercise, I expect this epidemic to continue.
Can new drugs really fix diabetes, or does it require social change?
It's a very interesting question. To some degree, lifestyle changes should be highly recommended to complement pharmaceutical
therapy regarding diabetic patients. Even if you have a genetic predisposition for such a disease, you still can mitigate
the intensity of the impact by adjusting your lifestyle.
Drug analysts are calling DPP-IV inhibitors the next blockbuster class. How do you go about creating this new class of drugs?
What do you look for?
What we really know and have experienced already is that the key opinion leaders are very excited about the new class. That's
always the first step—you have to make sure that KOLs are enthusiastic. I see a good level of this in the medical community
for the new classes, and we have to continue to nurture that excitement. This can be achieved by providing new clinical data,
developing fixed-dose combinations, and exploring if any new drugs can slow down the progression of diabetes. There is a lot
we expect to deliver over the next few years, which will continue to increase this level of excitement.
Direct-to-patient initiatives, which educate patients and communicate that there's a great treatment that can help them, are
really the next key step. This is certainly a category that can be built on, not only driving awareness with key opinion leaders,
but driving awareness among patients as well.
What has been the reaction from doctors and clinicians about Galvus, and in general about this new drug class?
Novartis has one of the most exciting, if not the most exciting, late-stage pipelines, and doctors and clinicians are responding
to that. We have done significant clinical studies with a lot of patients being enrolled, and we're very comfortable about
the efficacy and safety profile of Galvus. It's always great to have a new class where the drug is safe.